Setback For Autism Pioneer Seaside
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Phase II study testing arbaclofen for idiopathic autism showed no difference from placebo on a measure of social withdrawal but demonstrated significant improvement on disease severity and social function. That’s a hint the drug may yet be the first to affect the course of the disease and not just its symptoms – if a trial can be designed to test the right endpoint.